Research led by investigators from the University of Cambridge has shown that administration of the drug infliximab for newly-diagnosed patients of Crohn’s disease dramatically improves outcomes—including the reduction of people needing abdominal surgery for treatment by ten-fold. Results of the trial were published this week in The Lancet. Called the…

A new evidence-based guideline for use of blood- and stool-based biomarkers to help manage Crohn’s disease was released today by the American Gastroenterological Association (AGA). Crohn’s is a type of inflammatory bowel disease (IBD), a condition estimated to affect 2.74 million people in the U.S. alone. The guideline was published today in Gastroenterology. “Based on…

Direct injection of neonatal mesenchymal stem cells (MSCs) from discarded heart tissue from surgery could aid in healing Crohn’s disease, according to new research from investigators at the Ann & Robert H. Lurie Children’s Hospital of Chicago. The study, published in the journal Advanced Therapeutics, found that the technique, reduced…

An international research consortium, led by researchers of the Wellcome Sanger Institute and the Broad Institute of MIT and Harvard, has identified 10 new genetic variants linked to an elevated risk of developing Crohn’s disease (CD). The study, published today in Nature Genetics, is the largest of its kind to…

A team of international scientists lead by the University of Toronto have discovered an autoantibody detectable in blood that can be used as a biomarker to predict complicated Crohn’s disease up to seven years prior to diagnosis. The underlying mechanisms of Crohn’s disease, a type of Inflammatory Bowel Disease and…

Mount Sinai research shows how known genetic mutations can cause Crohn’s disease and also highlights a possible new treatment for patients who don’t respond to standard biologic therapy. It has been known for some time that mutations in the NOD2 gene, which plays an important role in recognizing bacteria and…

Two publications in Nature report on advances from the Human Cell Atlas (HCA) consortium, creating the most comprehensive Cell Atlas of the gut to date, identifying new targets for gut diseases, and laying out a framework for expansion of the project to other parts of the anatomy. The work was carried…

An undergraduate researcher from the University of Virginia (UVA) has discovered why children with relapsing Crohn’s disease suffer from repeated bouts of symptoms even after they have appeared to recover. The discovery showed that children with relapsing Crohn’s had a persistent disruption of their microbiomes even after their inflammation symptoms…

Research led by the Icahn School of Medicine at Mount Sinai, New York, has confirmed a link between the genetics of inflammatory bowel disease (IBD) and Parkinson’s disease. The team that discovered the connection hopes their findings can help design therapies that could target both conditions. “Our research not only…

A wireless sensor developed at the Northwestern University could help Crohn’s disease patients get faster, more effective treatment when they have a flare up. Inflammatory bowel diseases such as Crohn’s disease are predicted to affect more than seven million people around the world, with Crohn’s thought to affect at least…

Traditional vaccines work by teaching the immune system to recognize a virus or bacteria that needs to be attacked. Now, researchers at the University of Chicago’s Pritzker School of Molecular Engineering (PME) say they have developed a new vaccine that does just the opposite by removing the immune system’s memory…

New microbiome-based evidence suggests a two-drug combination, a blockade of both IL-22 and IL-1R, may treat inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis. This team studied “upstream cues” of microbial interactions with intestinal cells. They report that IL-22 and IL-1R can trigger “a chain reaction” that…

One day after announcing positive Phase II results from separate trials for ulcerative colitis and Crohn’s disease, Prometheus Biosciences announced pricing of a public stock offering intended to net $500 million for the company to fund Phase III clinical studies for both. The company’s therapeutic candidate, PRA023 is an IgG1…

Chronic diseases cover a wide range of medical conditions from asthma and diabetes to gastrointestinal and heart problems. As the U.S. Center for Disease Control and Prevention (CDC) notes: “Chronic diseases are defined broadly as conditions that last 1 year or more and require ongoing medical attention or limit activities…

Two research groups performed single-cell RNA sequencing (scRNA-seq) of immune cells and combined the data with fine mapping of autoimmune disease–associated genetic variants to provide a resource that allows the large-scale identification of genotype-phenotype interactions. The research, which is published in Science and brings together population genetics and scRNA-seq data,…